Table 5.
Antibiotic treatment in adults with CAP
| Antibiotic | Cohorts (n)a | Studies (n) | Patients treated with antibioticb, range (%) | References |
|---|---|---|---|---|
| Monotherapy | 31 | 7 | 16.0–94.7 | [22, 40, 41, 43, 44, 46, 47] |
| Beta-lactams | 32 | 8 | 5.0–87.7 | [22, 37, 38, 40, 41, 43, 44, 47] |
| Macrolides | 30 | 6 | 0.3–47.7 | [37, 38, 40, 41, 44, 47] |
| Quinolones | 32 | 8 | 2.0–46.0 | [22, 37, 38, 40, 41, 43, 44, 47] |
| Other | 26 | 3 | 0.7–8.8 | [40, 41, 43] |
| Combination therapy | 33 | 8 | 5.0–84.0 | [22, 37, 40, 41, 43, 44, 46, 47] |
| Beta-lactam + macrolide | 10 | 7 | 1.7–70.0 | [22, 38, 40, 43–45, 47] |
| Beta-lactam + quinolone | 4 | 4 | 6.3–63.0 | [22, 43, 44, 47] |
| Macrolide + quinolone | 2 | 2 | 0.9–1.0 | [44, 47] |
| Other | 5 | 4 | 2.0–38.0 | [38, 43, 44, 47] |
CAP community-acquired pneumonia
aFor studies that only reported data separately for each cohort, all cohorts were included; for studies that reported data for the overall study population, the summary data were used. Studies performed in patients with pneumonia due to a specific pathogen were excluded
bPercentages are based on patients with available data